Pharmafile Logo
Pharmafocus logo
Advanced Search

MHRA

Showing 15 posts of 105 posts found.

IMed Consultancy releases white paper on Digital Mental Health Technologies

October 20, 2025
Medical Communications Digital Mental Health Technologies, IMed Consultancy, MHRA

IMed Consultancy, a consultancy and service provider for the medical and health technology sector, has published a new white paper …

News

Dual immunotherapy for bowel cancer now available under NHS

April 23, 2025
Research and Development Bristol Myer Squibb, MHRA, NICE, Oncology, bowel cancer, colorectal cancer, immunotherapy

Dual immunotherapy, a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), has been granted extension in the UK by the Medicines …

News

MHRA approve new treatment combo for transplant-ineligible multiple myeloma patients

January 30, 2025
Research and Development MHRA, Oncology, approvals, multiple myeloma, rare diseases

The Medicine and Healthcare products Regulatory Agency (MHRA) has approved quadruplet therapy, SARCLISA (isatuximab) in combination to treat multiple myeloma …

News

New gastric & gastro-oesophageal junction cancer treatment VYLOYâ„¢ â–¼ (zolbetuximab): the first claudin 18.2 biomarker targeted therapy licensed in Great Britain

August 16, 2024
GEJ cancers, Gastrointestinal tract, MHRA, Oncology, gastric cancer

Claudin18.2 is an innovative drug-target which is not currently used for any other authorised treatment. There is a large unmet …

News
Press release

Ascendis Pharma’s Yorvipath approved by MHRA for hypoparathyroidism treatment

April 25, 2024
Medical Communications Ascendis Pharma, Internal Medicine, MHRA, hypoparathyroidism

Ascendis Pharma has announced that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation for Yorvipath …

News
robina-weermeijer-ihfopazzjhm-unsplash_5

MHRA approves Takeda’s Hyqvia for chronic inflammatory demyelinating polyneuropathy treatment

March 21, 2024
Medical Communications Hyqvia, MHRA, Neurology, Takeda, chronic inflammatory demyelinating polyneuropathy

Takeda has announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation to Hyqvia as a …

News

MHRA approves GSK’s Omjjara in Great Britain for splenomegaly treatment

January 31, 2024
Medical Communications GSK, MHRA, Omjjara, Oncology, myelofibrosis, splenomegaly

GSK has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted Marketing Authorisation to Omjjara (momelotinib) in …

News

MHRA approves Mounjaro for diabetes and weight management

January 26, 2024
Medical Communications Diabetes, MHRA, Mounjaro, weight management

The Medicines and Healthcare products Regulatory Agency (MHRA) has announced that it has approved a four-dose version of the diabetes …

News

Santhera gains MHRA approval for Agamree as treatment for Duchenne muscular dystrophy

January 12, 2024
Medical Communications Agamree, Duchenne Muscular Dystophy, MHRA, Musculo-skeletal disorder, santhera

Santhera Pharmamceuticals has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has approved Agamree (vamorolone) in the UK …

News

ViroCell and GOSH gain MHRA manufacturing approval

November 1, 2023
Manufacturing and Production Great Ormand Street Hospital, MHRA, Pharmacy, ViroCell, manufacturing, viral vectors

ViroCell Biologics has announced that it can now manufacture and export viral vectors from Great Ormand Street Hospital’s (GOSH) state-of-the-art …

News
headache

AbbVie’s Aquipta receives MHRA marketing authorisation

September 5, 2023
Sales and Marketing AbbVie, Aquipta, MHRA, Neurology, atogepant, migraines

AbbVie has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorisation for Aquipta (atogepant), …

News

Amicus Therapeutics’ Pompe disease treatment approved for use in UK

August 17, 2023
Medical Communications Amicus Therapeutics, MHRA, NICE, Pompe disease, Rare Diseases

Amicus Therapeutics has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorisation …

News
markus-spiske-dnbtfbnqlrc-unsplash_1

MHRA authorises GSK’s RSV vaccine for older adults

July 10, 2023
Medical Communications Arexvy, GSK, Infections and infestations, MHRA, RSV

GSK has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised its Arexvy respiratory syncytial virus (RSV) …

News

NICE recommends Otsuka’s Lupkynis (voclosporin) in combination treatment for active lupus nephritis

May 4, 2023
Medical Communications MHRA, NICE, Nephrology, Otsuka Pharmaceuticals, lupus nephritis

Otsuka Pharmaceuticals has announced that the National Institutes for Health and Care Excellence (NICE) has recommended Lupkynis (voclosporin) in combination …

News
img_4190-e1376666350337-web

New targeted lung cancer treatment coming to UK under MHRA scheme

July 15, 2021
MHRA, NSCLC, UK, brexit

The MHRA has issued an Early Access to Medicines Scheme (EAMS) positive scientific opinion for tepotinib, for the treatment of …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025